GlobeNewswire: Y-mAbs Therapeutics, Inc. Contains the last 10 of 157 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T09:49:40ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/14/2846337/0/en/Y-mAbs-Therapeutics-Announces-Resignation-of-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=49967Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer2024-03-14T13:05:00Z<![CDATA[NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his resignation. Y-mAbs has commenced a search process for a successor. Mr. Kruse will remain in the Chief Financial Officer role until his successor is identified and joins the Company. He will then continue as a non-executive employee from the time his successor joins the Company through July 31, 2024, after which it is expected that Mr. Kruse will be available to the Company for a period of time to support a smooth transition of the Chief Financial Officer role.]]>https://www.globenewswire.com/news-release/2024/03/04/2839442/0/en/Y-mAbs-Appoints-Oncology-Executive-Mary-Tagliaferri-M-D-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=49967Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors2024-03-04T12:30:00Z<![CDATA[Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development]]>https://www.globenewswire.com/news-release/2024/02/29/2838407/0/en/Y-mAbs-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Corporate-Developments.html?f=22&fvtc=4&fvtv=49967Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments2024-02-29T21:05:00Z<![CDATA[NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the quarter and full year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/02/16/2830703/0/en/Y-mAbs-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-and-Operating-Results-on-February-29-2024.html?f=22&fvtc=4&fvtv=49967Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 20242024-02-16T12:30:00Z<![CDATA[NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, March 1, 2024, at 8:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Vignesh Rajah, Chief Medical Officer; Thomas Gad, Founder, Vice Chair and Chief Business Officer; and Steen Lisby, Chief Scientific Officer.]]>https://www.globenewswire.com/news-release/2024/01/02/2802924/0/en/Y-mAbs-Therapeutics-to-Present-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=49967Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference2024-01-02T21:05:00Z<![CDATA[NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 5:15pm PT.]]>https://www.globenewswire.com/news-release/2023/12/13/2795869/0/en/Y-mAbs-Therapeutics-Added-to-the-NASDAQ-Biotechnology-Index.html?f=22&fvtc=4&fvtv=49967Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index2023-12-13T21:05:00Z<![CDATA[NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023.]]>https://www.globenewswire.com/news-release/2023/11/13/2779460/0/en/Y-mAbs-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Corporate-Developments.html?f=22&fvtc=4&fvtv=49967Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments2023-11-13T21:05:00Z<![CDATA[NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter of 2023.]]>https://www.globenewswire.com/news-release/2023/10/31/2770021/0/en/Y-mAbs-to-Announce-Third-Quarter-2023-Financial-and-Operating-Results-on-November-13-2023.html?f=22&fvtc=4&fvtv=49967Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 20232023-10-31T11:05:00Z<![CDATA[NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, November 14, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Thomas Gad, Founder, Vice Chair and Chief Business Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Steen Lisby, Chief Scientific Officer; and Vignesh Rajah, Chief Medical Officer.]]>https://www.globenewswire.com/news-release/2023/10/18/2762734/0/en/Y-mAbs-Names-Michael-Rossi-as-President-and-Chief-Executive-Officer-and-Director.html?f=22&fvtc=4&fvtv=49967Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director2023-10-18T20:05:00Z<![CDATA[NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced today that its Board of Directors has appointed Michael Rossi as President and Chief Executive Officer (“CEO”) and a member of the Board of Directors with an expected start date of November 6, 2023. Mr. Rossi brings more than 30 years of experience in the radiopharmaceutical industry, including building out and leading the U.S. Business for Advanced Accellerators Applications (“AAA”), a Novartis company, led the growth of Jubilant Radiopharm into a vertically integrated radiopharmaceutical leader, and spent after over a decade at GE Healthcare and, more recently, served as President, Medical Group at Mirion Technologies, Inc. (“Mirion”). In connection with Mr. Rossi’s appointment, Thomas Gad, who founded Y-mAbs in 2015 and has served as President and Head of Business Development and Strategy (since 2015) and Interim CEO (since 2022) of the Company, will cease serving in those offices and assume the roles of Vice Chairman of the Board of Directors and Chief Business Officer of the Company, in each case effective as of Mr. Rossi’s start date.]]>https://www.globenewswire.com/news-release/2023/10/17/2761907/0/en/Y-mAbs-Therapeutics-Announces-U-S-FDA-Clearance-of-Investigational-New-Drug-Application-for-CD38-SADA.html?f=22&fvtc=4&fvtv=49967Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA2023-10-17T20:05:00Z<![CDATA[Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company’s novel SADA technology platform Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company’s novel SADA technology platform]]>